MediWound Ltd. (MDWD) Form 6-K — May 27, 2026
MediWound reported Q1 2026 revenue of $1.5 million, a 62.5% decline from $4.0 million in the prior year, driven by timing of BARDA-related revenues and postponed shipments due to regional conflict. The company posted a net loss of $3.0 million ($0.23 per share) and an operating loss of $8.0 million, compared to a net loss of $0.7 million and operating loss of $5.2 million in Q1 2025. Despite the near-term financial weakness, MediWound reaffirmed its full-year 2026 revenue guidance of $24-26 million, citing expected revenue from government-related development services in the second half of the year.
Key figures
- Revenue
- 1475000
- Guidance
- $24-26 million for full-year 2026
- Total Assets
- 79982000
- Cash Position
- 44646000
- Rd Expenses
- 5185000
- Gross Margin
- 21.9
- Gross Profit
- 323000
- Shares Outstanding
- 12874062
- Barda Contract Value
- 197000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.